Transcatheter or Surgical Treatment of Aortic-Valve Stenosis
Stefan Blankenberg,Moritz Seiffert,Reinhard Vonthein,Helmut Baumgartner,Sabine Bleiziffer,Michael A Borger,Yeong-Hoon Choi,Peter Clemmensen,Jochen Cremer,Martin Czerny,Nina Diercks,Ingo Eitel,Stephan Ensminger,Derk Frank,Norbert Frey,Andreas Hagendorff,Christian Hagl,Christian Hamm,Utz Kappert,Matthias Karck,Won-Keun Kim,Inke R König,Markus Krane,Ulf Landmesser,Axel Linke,Lars S Maier,Steffen Massberg,Franz-Josef Neumann,Hermann Reichenspurner,Tanja K Rudolph,Christof Schmid,Holger Thiele,Raphael Twerenbold,Thomas Walther,Dirk Westermann,Erion Xhepa,Andreas Ziegler,Volkmar Falk,DEDICATE-DZHK6 Trial Investigators,Jörg W Schröder,Rüdiger Autschbach,Anno Diegeler,Sebastian Kerber,René Schramm,Tanja K Rudolf,Mohammad Sherif,Verena Stangl,Stephan Kische,Hüseyin Ince,Christian Butter,Johannes Albes,Justus Strauch,Andreas Mügge,Oliver Ritter,Tobias Zeus,Artur Lichtenberg,Stephan Achenbach,Oliver Dewald,Tienush Rassaf,Markus Kamler,David Leistner,Constantin von Zur Mühlen,Wolfgang Bothe,Oliver Dörr,Peter Roth,Hassina Baraki,Tim Seidler,Alexander Kaminski,Marcus Dörr,Britt Hofmann,Daniel Sedding,Lenard Conradi,Johann Bauersachs,Fabio Ius,Anna Meyer,Florian Leuschner,Christian Schulze,Torsten Doenst,Jörg Jöckel,Richard Feyrer,Elmar Kuhn,Stephan Baldus,Michael Borger,George Awad,Rüdiger Braun-Dullaeus,Ralph Stephan von Bardeleben,Daniel-Sebastian Dohle,Stephanie Voss,Michael Joner,Sven Martens,Lars Maier,Raffi Bekeredjian,Ulrich Franke,Wolfgang Rottbauer,Andreas Liebold
DOI: https://doi.org/10.1056/NEJMoa2400685
2024-05-02
Abstract:Background: Among low-risk patients with severe, symptomatic aortic stenosis who are eligible for both transcatheter aortic-valve implantation (TAVI) and surgical aortic-valve replacement (SAVR), data are lacking on the appropriate treatment strategy in routine clinical practice. Methods: In this randomized noninferiority trial conducted at 38 sites in Germany, we assigned patients with severe aortic stenosis who were at low or intermediate surgical risk to undergo either TAVI or SAVR. Percutaneous- and surgical-valve prostheses were selected according to operator discretion. The primary outcome was a composite of death from any cause or fatal or nonfatal stroke at 1 year. Results: A total of 1414 patients underwent randomization (701 to the TAVI group and 713 to the SAVR group). The mean (±SD) age of the patients was 74±4 years; 57% were men, and the median Society of Thoracic Surgeons risk score was 1.8% (low surgical risk). The Kaplan-Meier estimate of the primary outcome at 1 year was 5.4% in the TAVI group and 10.0% in the SAVR group (hazard ratio for death or stroke, 0.53; 95% confidence interval [CI], 0.35 to 0.79; P<0.001 for noninferiority). The incidence of death from any cause was 2.6% in the TAVI group and 6.2% in the SAVR group (hazard ratio, 0.43; 95% CI, 0.24 to 0.73); the incidence of stroke was 2.9% and 4.7%, respectively (hazard ratio, 0.61; 95% CI, 0.35 to 1.06). Procedural complications occurred in 1.5% and 1.0% of patients in the TAVI and SAVR groups, respectively. Conclusions: Among patients with severe aortic stenosis at low or intermediate surgical risk, TAVI was noninferior to SAVR with respect to death from any cause or stroke at 1 year. (Funded by the German Center for Cardiovascular Research and the German Heart Foundation; DEDICATE-DZHK6 ClinicalTrials.gov number, NCT03112980.).